NCT05727761

Pioglitazone-Metformin Combination Treatment for High Risk Oral Preneoplasia

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 36 (estimated)
• Sponsor: University of Minnesota · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a Phase IIa oral cavity leukoplakia study of pioglitazone 15mg and metformin 500mg BID for 12 weeks. The primary objective is to determine the clinical and histologic changes of leukoplakia from baseline following a 12 week course of twice daily pioglitazone-metformin. Outcomes are defined as are a reduction of the leukoplakia grade in \> 50% of treated participants and a partial or complete clinical response defined as 50% or greater reduction in the sum of measured targeted lesions. In addition, participants who show clinical and histologic improvement should correlate with a significant reduction of Ki-67 proliferative indices in lesions of these participants as compared to baseline.

Conditions

• Oral Leukoplakia

Interventions

Type	Name	Description
DRUG	pioglitazone-metformin	Treatment with pioglitazone-metformin (15mg/500mg) twice a day for 12 weeks

Timeline

• Start date: 2025-01-01
• Primary completion: 2026-07-28
• Completion: 2026-07-28
• First posted: 2023-02-14
• Last updated: 2025-12-24

Locations

2 sites across 1 country: United States

Regulatory

• FDA-regulated drug study